Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803

NCT00276172 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00276172
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00276172 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Natalizumab in Subjects With Multiple Sclerosis Who Have Completed Studies C-1801, C-1802, or C-1803
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
January 31, 2006
Enrollment
1,615 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis